KRRO:NASDAQKorro Bio, Inc. Analysis

Korro Bio’s stock is trading at $13.69, comfortably above its 20‑day ($12.05) and 50‑day ($11.94) SMAs but still below the long‑term 200‑day SMA ($18.66), indicating a short‑term bullish tilt within a broader neutral framework. The RSI sits at 60.4 and the MACD line is above its signal, both pointing to modest momentum, while the price is sandwiched between a solid support zone around $9.90 and resistance near $15.55. However, the equity exhibits extreme volatility (≈90% 30‑day) and a high beta of 3.34, underscoring susceptibility to market swings, and its historical max drawdown of –89.7% highlights the downside risk.
Fundamentally, KRRO is distressed: revenue shrank 43% to $6.39 M, the company posted a net loss of $117.3 M for 2025, and earnings per share remain deeply negative (‑$12.48 trailing, ‑$7.59 forward). The balance sheet shows $75 M cash versus $43 M debt (debt‑to‑equity 84.5), yet operating cash flow is strongly negative, and valuation multiples are stretched (price‑to‑sales ~31×, price‑to‑book 2.5×). Recent material news highlights progress on the KRRO‑121 RNA‑editing candidate and a notable insider purchase of $2.3 M at $11.11, suggesting some confidence despite the challenging financial backdrop.